156 related articles for article (PubMed ID: 36456573)
1. Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
Lang JE; Forero-Torres A; Yee D; Yau C; Wolf D; Park J; Parker BA; Chien AJ; Wallace AM; Murthy R; Albain KS; Ellis ED; Beckwith H; Haley BB; Elias AD; Boughey JC; Yung RL; Isaacs C; Clark AS; Han HS; Nanda R; Khan QJ; Edmiston KK; Stringer-Reasor E; Price E; Joe B; Liu MC; Brown-Swigart L; Petricoin EF; Wulfkuhle JD; Buxton M; Clennell JL; Sanil A; Berry S; Asare SM; Wilson A; Hirst GL; Singhrao R; Asare AL; Matthews JB; Melisko M; Perlmutter J; Rugo HS; Symmans WF; van 't Veer LJ; Hylton NM; DeMichele AM; Berry DA; Esserman LJ
NPJ Breast Cancer; 2022 Dec; 8(1):128. PubMed ID: 36456573
[TBL] [Abstract][Full Text] [Related]
2. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
Nanda R; Liu MC; Yau C; Shatsky R; Pusztai L; Wallace A; Chien AJ; Forero-Torres A; Ellis E; Han H; Clark A; Albain K; Boughey JC; Jaskowiak NT; Elias A; Isaacs C; Kemmer K; Helsten T; Majure M; Stringer-Reasor E; Parker C; Lee MC; Haddad T; Cohen RN; Asare S; Wilson A; Hirst GL; Singhrao R; Steeg K; Asare A; Matthews JB; Berry S; Sanil A; Schwab R; Symmans WF; van 't Veer L; Yee D; DeMichele A; Hylton NM; Melisko M; Perlmutter J; Rugo HS; Berry DA; Esserman LJ
JAMA Oncol; 2020 May; 6(5):676-684. PubMed ID: 32053137
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.
Albain KS; Yau C; Petricoin EF; Wolf DM; Lang JE; Chien AJ; Haddad T; Forero-Torres A; Wallace AM; Kaplan H; Pusztai L; Euhus D; Nanda R; Elias AD; Clark AS; Godellas C; Boughey JC; Isaacs C; Tripathy D; Lu J; Yung RL; Gallagher RI; Wulfkuhle JD; Brown-Swigart L; Krings G; Chen YY; Potter DA; Stringer-Reasor E; Blair S; Asare SM; Wilson A; Hirst GL; Singhrao R; Buxton M; Clennell JL; Sanil A; Berry S; Asare AL; Matthews JB; DeMichele AM; Hylton NM; Melisko M; Perlmutter J; Rugo HS; Symmans WF; Van't Veer LJ; Yee D; Berry DA; Esserman LJ
Clin Cancer Res; 2024 Feb; 30(4):729-740. PubMed ID: 38109213
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer.
Jhaveri K; Wang R; Teplinsky E; Chandarlapaty S; Solit D; Cadoo K; Speyer J; D'Andrea G; Adams S; Patil S; Haque S; O'Neill T; Friedman K; Esteva FJ; Hudis C; Modi S
Breast Cancer Res; 2017 Aug; 19(1):89. PubMed ID: 28764748
[TBL] [Abstract][Full Text] [Related]
5. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.
Pusztai L; Yau C; Wolf DM; Han HS; Du L; Wallace AM; String-Reasor E; Boughey JC; Chien AJ; Elias AD; Beckwith H; Nanda R; Albain KS; Clark AS; Kemmer K; Kalinsky K; Isaacs C; Thomas A; Shatsky R; Helsten TL; Forero-Torres A; Liu MC; Brown-Swigart L; Petricoin EF; Wulfkuhle JD; Asare SM; Wilson A; Singhrao R; Sit L; Hirst GL; Berry S; Sanil A; Asare AL; Matthews JB; Perlmutter J; Melisko M; Rugo HS; Schwab RB; Symmans WF; Yee D; Van't Veer LJ; Hylton NM; DeMichele AM; Berry DA; Esserman LJ
Cancer Cell; 2021 Jul; 39(7):989-998.e5. PubMed ID: 34143979
[TBL] [Abstract][Full Text] [Related]
6. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
Rugo HS; Olopade OI; DeMichele A; Yau C; van 't Veer LJ; Buxton MB; Hogarth M; Hylton NM; Paoloni M; Perlmutter J; Symmans WF; Yee D; Chien AJ; Wallace AM; Kaplan HG; Boughey JC; Haddad TC; Albain KS; Liu MC; Isaacs C; Khan QJ; Lang JE; Viscusi RK; Pusztai L; Moulder SL; Chui SY; Kemmer KA; Elias AD; Edmiston KK; Euhus DM; Haley BB; Nanda R; Northfelt DW; Tripathy D; Wood WC; Ewing C; Schwab R; Lyandres J; Davis SE; Hirst GL; Sanil A; Berry DA; Esserman LJ;
N Engl J Med; 2016 Jul; 375(1):23-34. PubMed ID: 27406347
[TBL] [Abstract][Full Text] [Related]
7. Adaptive Randomization of Neratinib in Early Breast Cancer.
Park JW; Liu MC; Yee D; Yau C; van 't Veer LJ; Symmans WF; Paoloni M; Perlmutter J; Hylton NM; Hogarth M; DeMichele A; Buxton MB; Chien AJ; Wallace AM; Boughey JC; Haddad TC; Chui SY; Kemmer KA; Kaplan HG; Isaacs C; Nanda R; Tripathy D; Albain KS; Edmiston KK; Elias AD; Northfelt DW; Pusztai L; Moulder SL; Lang JE; Viscusi RK; Euhus DM; Haley BB; Khan QJ; Wood WC; Melisko M; Schwab R; Helsten T; Lyandres J; Davis SE; Hirst GL; Sanil A; Esserman LJ; Berry DA;
N Engl J Med; 2016 Jul; 375(1):11-22. PubMed ID: 27406346
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.
Symmans WF; Yau C; Chen YY; Balassanian R; Klein ME; Pusztai L; Nanda R; Parker BA; Datnow B; Krings G; Wei S; Feldman MD; Duan X; Chen B; Sattar H; Khazai L; Zeck JC; Sams S; Mhawech-Fauceglia P; Rendi M; Sahoo S; Ocal IT; Fan F; LeBeau LG; Vinh T; Troxell ML; Chien AJ; Wallace AM; Forero-Torres A; Ellis E; Albain KS; Murthy RK; Boughey JC; Liu MC; Haley BB; Elias AD; Clark AS; Kemmer K; Isaacs C; Lang JE; Han HS; Edmiston K; Viscusi RK; Northfelt DW; Khan QJ; Leyland-Jones B; Venters SJ; Shad S; Matthews JB; Asare SM; Buxton M; Asare AL; Rugo HS; Schwab RB; Helsten T; Hylton NM; van 't Veer L; Perlmutter J; DeMichele AM; Yee D; Berry DA; Esserman LJ
JAMA Oncol; 2021 Nov; 7(11):1654-1663. PubMed ID: 34529000
[TBL] [Abstract][Full Text] [Related]
9. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
Nitz U; Gluz O; Graeser M; Christgen M; Kuemmel S; Grischke EM; Braun M; Augustin D; Potenberg J; Krauss K; Schumacher C; Forstbauer H; Reimer T; Stefek A; Fischer HH; Pelz E; Zu Eulenburg C; Kates R; Wuerstlein R; Kreipe HH; Harbeck N;
Lancet Oncol; 2022 May; 23(5):625-635. PubMed ID: 35405088
[TBL] [Abstract][Full Text] [Related]
10. MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
Chien AJ; Tripathy D; Albain KS; Symmans WF; Rugo HS; Melisko ME; Wallace AM; Schwab R; Helsten T; Forero-Torres A; Stringer-Reasor E; Ellis ED; Kaplan HG; Nanda R; Jaskowiak N; Murthy R; Godellas C; Boughey JC; Elias AD; Haley BB; Kemmer K; Isaacs C; Clark AS; Lang JE; Lu J; Korde L; Edmiston KK; Northfelt DW; Viscusi RK; Yee D; Perlmutter J; Hylton NM; Van't Veer LJ; DeMichele A; Wilson A; Peterson G; Buxton MB; Paoloni M; Clennell J; Berry S; Matthews JB; Steeg K; Singhrao R; Hirst GL; Sanil A; Yau C; Asare SM; Berry DA; Esserman LJ;
J Clin Oncol; 2020 Apr; 38(10):1059-1069. PubMed ID: 32031889
[TBL] [Abstract][Full Text] [Related]
11. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
[TBL] [Abstract][Full Text] [Related]
12. A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).
Patel TA; Ensor JE; Creamer SL; Boone T; Rodriguez AA; Niravath PA; Darcourt JG; Meisel JL; Li X; Zhao J; Kuhn JG; Rosato RR; Qian W; Belcheva A; Schwartz MR; Kaklamani VG; Chang JC
Breast Cancer Res; 2019 Sep; 21(1):100. PubMed ID: 31477168
[TBL] [Abstract][Full Text] [Related]
13. Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes.
Friedland JC; Smith DL; Sang J; Acquaviva J; He S; Zhang C; Proia DA
Invest New Drugs; 2014 Feb; 32(1):14-24. PubMed ID: 23686707
[TBL] [Abstract][Full Text] [Related]
14. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
[TBL] [Abstract][Full Text] [Related]
16. NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2
Jacobs SA; Robidoux A; Abraham J; Pérez-Garcia JM; La Verde N; Orcutt JM; Cazzaniga ME; Piette F; Antolín S; Aguirre E; Cortes J; Llombart-Cussac A; Di Cosimo S; Kim RS; Feng H; Lipchik C; Lucas PC; Srinivasan A; Wang Y; Song N; Gavin PG; Balousek AD; Paik S; Allegra CJ; Wolmark N; Pogue-Geile KL
Breast Cancer Res; 2019 Dec; 21(1):133. PubMed ID: 31796073
[TBL] [Abstract][Full Text] [Related]
17. Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy.
Du L; Yau C; Brown-Swigart L; Gould R; Krings G; Hirst GL; Bedrosian I; Layman RM; Carter JM; Klein M; Venters S; Shad S; van der Noordaa M; Chien AJ; Haddad T; Isaacs C; Pusztai L; Albain K; Nanda R; Tripathy D; Liu MC; Boughey J; Schwab R; Hylton N; DeMichele A; Perlmutter J; Yee D; Berry D; Van't Veer L; Valero V; Esserman LJ; Symmans WF
Ann Oncol; 2021 May; 32(5):642-651. PubMed ID: 33617937
[TBL] [Abstract][Full Text] [Related]
18. Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer.
Xiang L; Gilkes DM; Chaturvedi P; Luo W; Hu H; Takano N; Liang H; Semenza GL
J Mol Med (Berl); 2014 Feb; 92(2):151-64. PubMed ID: 24248265
[TBL] [Abstract][Full Text] [Related]
19. Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer-A Study of the GANNET53 Consortium.
Ray-Coquard I; Braicu I; Berger R; Mahner S; Sehouli J; Pujade-Lauraine E; Cassier PA; Moll UM; Ulmer H; Leunen K; Zeimet AG; Marth C; Vergote I; Concin N
Front Oncol; 2019; 9():832. PubMed ID: 31552170
[No Abstract] [Full Text] [Related]
20. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
